Please note that due to a high volume of submissions, the ANZCTR is currently experiencing a delay in processing of submissions.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00190684




Registration number
NCT00190684
Ethics application status
Date submitted
12/09/2005
Date registered
19/09/2005
Date last updated
17/01/2011

Titles & IDs
Public title
Long-Term, Open Label Atomoxetine Study
Scientific title
Long-Term, Open Label Safety Study of Atomoxetine Hydrochloride in Patients, 6 Years and Older With Attention-Deficit/Hyperactivity Disorder
Secondary ID [1] 0 0
B4Z-MC-LYAI
Secondary ID [2] 0 0
4331
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Attention Deficit Hyperactivity Disorder 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - atomoxetine

Experimental: Atomoxetine - Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.


Treatment: Drugs: atomoxetine
0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study - Vital signs were assesed categorically using the term high for BP, high and low for pulse and temperature, or decreased for weight. For BP, high was an increase to a value above the 95th percentile of the National Institute of Health (NIH) values. For pulse, high was an increase of at least 25 beats per minute to at least 110, and low was a decrease of at least 20 beats per minute to at most 65 beats per minute. For temperature, high was an increase of at least 1 to 37.7 and low was a decrease of at least 1.3 to at most 35.6. Decrease in weight was marked by a reduction of at least 3.5%.
Timepoint [1] 0 0
Baseline through 5 years
Primary outcome [2] 0 0
Change From Baseline to 5 Year Endpoint in BP
Timepoint [2] 0 0
baseline, 5 years
Primary outcome [3] 0 0
Change From Baseline to 5 Year Endpoint in Pulse
Timepoint [3] 0 0
baseline, 5 years
Primary outcome [4] 0 0
Change From Baseline to 5 Year Endpoint in Body Weight
Timepoint [4] 0 0
baseline, 5 years
Primary outcome [5] 0 0
Change From Baseline to 5 Year Endpoint in Height
Timepoint [5] 0 0
baseline, 5 years
Primary outcome [6] 0 0
Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile - Patients were assessed for changes in weight, height, and BMI. BMI is an estimate of body fat based on body weight divided by height squared.
Timepoint [6] 0 0
baseline, 5 years
Primary outcome [7] 0 0
Change From Baseline to 5 Year Endpoint in Electrocardiogram (ECG) - Patients were assessed for changes in ECG. The RR interval is the time duration between two consecutive R waves of the ECG. The QRS interval is the beginning of Q to the end of the S wave. The QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate. A corrected QT interval (QTc) has been corrected in order to aid interpretation. QTbz is the QT interval using Bazett's correction formula. QTfr is the QT interval using Fridericia's correction formula.QTdat is the QT interval using a data specific correction method for children.
Timepoint [7] 0 0
baseline, 5 years
Primary outcome [8] 0 0
Change From Baseline to 5 Year Endpoint in Heart Rate - Patients were assessed for changes in heart rate using electrocardiogram.
Timepoint [8] 0 0
baseline, 5 years
Primary outcome [9] 0 0
Number of Patients Meeting Committee for Proprietary Medicinal Products (CPMP) Categorical QTc Interval Criteria Part I (Numerical Increase) - QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate. A corrected QT interval (QTc) has been corrected in order to aid interpretation. QTbz is the QT interval using Bazett's correction formula. QTfr is the QT interval using Fridericia's correction formula. QTdat is the QT interval using a data specific correction method for children.
Timepoint [9] 0 0
baseline through 5 years
Primary outcome [10] 0 0
Number of Patients Meeting CPMP Categorical QTc Interval Criteria Part II (Interpretation at Baseline and Endpoint) - QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate. A corrected QT interval (QTc) has been corrected in order to aid interpretation. QTbz is the QT interval using Bazett's correction formula. QTfr is the QT interval using Fridericia's correction formula. QTdat is the QT interval using a data specific correction method for children. For Males: Normal is <430 ms, Borderline is >=430 ms and <450 ms, Prolonged is >=450 ms. For Females: Normal is <450 ms, Borderline is >=450 ms and <470 ms, Prolonged is >=470 ms.
Timepoint [10] 0 0
baseline through 5 years
Primary outcome [11] 0 0
Number of Participants With Abnormal Laboratory Analytes During the Study - Standard reference ranges from Covance Laboratories were used in the determination of abnormal high and low values based on age and gender, where appropriate. Aspartate aminotransferase (AST); serum glutamic oxaloacetic transaminase (SGOT); units/liter (U/L); alanine aminotransferase (ALT); serum glutamic pyruvic transaminase (SGPT); millimoles/liter (mmol/L); grams/liter (g/L); micromoles/liter (umol/L); millimoles/liter-iron (mmol/L-Fe); trillion/liter (TI/L)or 10^12 units/liter; Giga/liter (GI/L)or 10^9 units/liter; femtoliters (fL); urinalysis (UA)
Timepoint [11] 0 0
baseline through 5 years
Primary outcome [12] 0 0
Number of Participants in Each Tanner Stage (Pubic Hair) by Age Group - Tanner Stage:
I: no pubic hair at all (prepubertal Dominic state) II: small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum (males) or on the labia majora (females) III: hair becomes more coarse and curly, and begins to extend laterally IV: adult-like hair quality, extending across pubis but sparing medial thighs V: hair extends to medial surface of the thighs
Age Groups:
age<11.0 (female) and age<12 (male)
11=<age<12 (female) or 12<=age<13 (male)
12=<age<15 (female) or 13=<age<15 (male)
age>=15 (female and male)
Timepoint [12] 0 0
1 year through 5 years
Secondary outcome [1] 0 0
Change From Baseline to 5 Year Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score and Subscale Scores - Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of ADHD. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54. Hyperactive/Impulsive and Inattention Subscales consisted of 9 items each, for total subscale score range of 0 to 27. ADHD Index Subscale consisted of 12 items, for total score range of 0 to 36.
Timepoint [1] 0 0
baseline, 5 years
Secondary outcome [2] 0 0
Change From Baseline to 5 Year Endpoint in Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S) Score - Measures severity of the patient's overall severity of ADHD symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).
Timepoint [2] 0 0
baseline, 5 years
Secondary outcome [3] 0 0
Change From Baseline to 5 Year Endpoint in Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) Subscale Scores - A 27-item rating scale (0 [not at all/never] to 3 [very much true/very often]) completed by the parent to assess problem behaviors related to ADHD. Subscales: Oppositional, Cognitive Problems, Hyperactivity, and ADHD Index. Subscale total scores range from 0 to 18 for all subscales except ADHD Index which ranges from 0 to 36.
Timepoint [3] 0 0
baseline, 5 years
Secondary outcome [4] 0 0
Change From Baseline to 5 Year Endpoint in the Stroop Word Color Test - Only patients who took the Stroop Color Word Test in a previous atomoxetine study were required to complete the Stroop in this study. Stroop measures inhibition of dominant response and interference control. Patients were given tasks of recognition (colors), reading (where a word represents a color), and interference (reading words written in different colors). There were 100 items for each of the three categories and if they made it through 100 words with time remaining, they would repeat the list. Only a small number of patients had Stroop tests in this study, so no analysis was done.
Timepoint [4] 0 0
baseline, 5 years

Eligibility
Key inclusion criteria
- Must be at least 6 years old but less than 18 years old when enrolled in first
atomoxetine study

- Must meet the study criteria for ADHD

- Must be willing to have blood drawn and to complete other test required for this study
Minimum age
6 Years
Maximum age
18 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- allergic to more than 1 kind of medicine or have had multiple bad reactions to any
drug

- taking certain medicines that could interact with atomoxetine

- plan to move too far away from a doctor participating in this study in the next 5
years

- current or past history of any of the following: alcohol or drug abuse within the past
3 months, bipolar I or II disorder, high blood pressure, organic brain disease or
seizures, psychosis, other disorders or conditions diagnosed by a doctor that might
make you unsuitable to participate in this study

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Wallsend
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - South Brisbane
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - West Perth
Recruitment postcode(s) [1] 0 0
2287 - Wallsend
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
6005 - West Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oklahoma
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Rhode Island
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
United States of America
State/province [30] 0 0
Wisconsin
Country [31] 0 0
Belgium
State/province [31] 0 0
Antwerpen
Country [32] 0 0
Belgium
State/province [32] 0 0
Leuven
Country [33] 0 0
Canada
State/province [33] 0 0
Alberta
Country [34] 0 0
Canada
State/province [34] 0 0
Nova Scotia
Country [35] 0 0
Canada
State/province [35] 0 0
Ontario
Country [36] 0 0
Canada
State/province [36] 0 0
Quebec
Country [37] 0 0
France
State/province [37] 0 0
Bordeaux Cedex
Country [38] 0 0
France
State/province [38] 0 0
Lyon
Country [39] 0 0
France
State/province [39] 0 0
Paris Cedex 12
Country [40] 0 0
France
State/province [40] 0 0
Paris
Country [41] 0 0
Germany
State/province [41] 0 0
Heiligenstadt/Ofr
Country [42] 0 0
Germany
State/province [42] 0 0
Mannheim
Country [43] 0 0
Israel
State/province [43] 0 0
Holon
Country [44] 0 0
Israel
State/province [44] 0 0
Ness Ziona
Country [45] 0 0
Italy
State/province [45] 0 0
Cagliari
Country [46] 0 0
Italy
State/province [46] 0 0
Pisa
Country [47] 0 0
Netherlands
State/province [47] 0 0
Groningen
Country [48] 0 0
Netherlands
State/province [48] 0 0
Utrecht
Country [49] 0 0
Norway
State/province [49] 0 0
Oslo
Country [50] 0 0
Puerto Rico
State/province [50] 0 0
Rio Piedras
Country [51] 0 0
Puerto Rico
State/province [51] 0 0
San Juan
Country [52] 0 0
South Africa
State/province [52] 0 0
Sandown
Country [53] 0 0
South Africa
State/province [53] 0 0
Garsfontein
Country [54] 0 0
South Africa
State/province [54] 0 0
Panorama
Country [55] 0 0
Sweden
State/province [55] 0 0
Goteburg
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Scotland
Country [57] 0 0
United Kingdom
State/province [57] 0 0
South Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To learn about the safety and any side effects of atomoxetine when given to children and
adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children
and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for
about 5 years (long-term).

Study participants can be atomoxetine naive, atomoxetine experienced whose therapy has been
interrupted or, atomoxetine experienced on a known stable dose.
Trial website
https://clinicaltrials.gov/show/NCT00190684
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-619-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications